Zoth Lota S. 4

What Happened

• Director Zoth Lota S. received an award of 31,000 derivative securities (reported as an option award) from enGene Therapeutics Inc. on 2026-06-16. The filing shows an acquisition price of $0.00 (i.e., no cash paid at grant). The reported transaction is an award/acquisition (transaction code A), not a sale.

Key Details

• Transaction date: 2026-06-16; filing date: 2026-06-17 (filed the next day).
• Reported consideration: $0.00 per share (grant award); total reported cash paid = $0.
• Security type: derivative (option award) — 31,000 underlying shares.
• Vesting note (footnote): the option vests in full on the earlier of (i) the first anniversary of the vesting commencement date (vesting commencement date was June 9, 2026) or (ii) the registrant’s 2027 annual meeting of shareholders.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Timeliness: filing appears timely (filed the day after the reported transaction).

Context

• This was a grant of an option award (a derivative), not an immediate purchase of common shares; the director will only be able to own the underlying shares after vesting and any required exercise. Grants are common for director compensation and do not by themselves indicate immediate buying or selling activity.